NorthWest Biotherapeutics Inc (NWBO)

[Know-Fear]

Eight Is Enough?* One of the many benefits of mRNA technology is it enables pivoting (adapting) vaccines to new variants quicker. Phase 1 is primarily testing for safety. Assuming phase 1 is successful expect some pivoting going forward. Said pivoting likely resulting in different mixes of epitopes and/or additional epitopes to attempt to achieve a level of efficacy (see Horseb4CarT post 606041). Any level of efficacy likely resulting in a suite of different vaccines.


*apologies for borrowing from title of late 70’s sitcom/drama (in this instance I’d bet the under of the current mix of eight being enough. While noting a successful phase 1 for. safety is attainable and will likely get some media attention….as the cool new stuff tends garner media attention.)